We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
+15.71%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.92B
AUM Growth
+$466M
(+8.6%)
Cap. Flow
-$28.9M
Cap. Flow
% of AUM
-0.49%
Top 10 Holdings %
Top 10 Hldgs %
26.27%
Holding
163
New
16
Increased
58
Reduced
30
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
+$87.6M |
| 2 |
Guardant Health
GH
|
+$61.3M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$37.2M |
| 4 |
Toast
TOST
|
+$32M |
| 5 |
Lithia Motors
LAD
|
+$28.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$71.9M |
| 2 |
Doximity
DOCS
|
+$45M |
| 3 |
Enphase Energy
ENPH
|
+$36M |
| 4 |
Roper Technologies
ROP
|
+$31.6M |
| 5 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$31.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.76% |
| 2 | Technology | 22.95% |
| 3 | Industrials | 13.17% |
| 4 | Consumer Discretionary | 7.97% |
| 5 | Utilities | 3.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
RXO
RXO
$3.39B
| – | – |
-115,000
| Closed | -$2.26M |
|
|
TRML
152
DELISTED
Tourmaline Bio
TRML
| – | – |
-156,109
| Closed | -$2.93M |
|
153
WEC Energy
WEC
$35.8B
| – | – |
-94,165
| Closed | -$8.93M |
|
154
XPO
XPO
$23.4B
| – | – |
-208
| Closed | -$6.63K |
|
|
GTM
155
ZoomInfo Technologies
GTM
$978M
| – | – |
-1,067
| Closed | -$26.4K |
|
156
ZipRecruiter
ZIP
$324M
| – | – |
-817,475
| Closed | -$13M |
|
157
Zoetis
ZTS
$31.9B
| – | – |
-2,015
| Closed | -$335K |
|
|
FRLN
158
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| – | – |
-313,509
| Closed | -$2.16M |
|
|
ICPT
159
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-501,033
| Closed | -$6.73M |
|
|
VECT
160
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| – | – |
-3,675,644
| Closed | -$31.6M |
|
|
BLU
161
DELISTED
BELLUS Health Inc.
BLU
| – | – |
-2,210,000
| Closed | -$15.9M |
|
|
RXDX
162
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-670,020
| Closed | -$71.9M |
|
Similar funds
HPG
EMPI
RCG
JWBC
AAM
AA
CM
CIS
Eventide Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, Eventide Asset Management held 163 positions worth $5.92B, up 8.6% from $5.45B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Eventide Asset Management's Q2 2023 filing shows 16 new, 58 increased, 30 reduced and 24 closed positions. Its largest new stake was Toast: 1,603,866 shares worth $36.2M. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $71.9M.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 43% a quarter earlier, followed by Technology and Industrials.
- Eventide Asset Management's largest Q2 2023 buy was Toast: 1,603,866 shares worth $36.2M.
- Eventide Asset Management added most to Zentalis Pharmaceuticals in Q2 2023, an estimated $87.6M increase.
- Eventide Asset Management's biggest Q2 2023 reduction was Doximity, cutting an estimated $45M.
- Eventide Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $71.9M.
- Eventide Asset Management's ten largest holdings make up 26% of its $5.92B portfolio in Q2 2023.
- Eventide Asset Management opened 16 new positions and closed 24 in Q2 2023.
- Eventide Asset Management's portfolio value rose 8.6% quarter-over-quarter to $5.92B.
Based on Eventide Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.